Today: 10 April 2026
Subscribe
Browse Category

NASDAQ:TVTX 24 December 2025 - 13 January 2026

Ligand Pharmaceuticals stock slides as FDA pushes back Travere’s Filspari decision to April 13

Ligand Pharmaceuticals stock slides as FDA pushes back Travere’s Filspari decision to April 13

Ligand Pharmaceuticals shares fell 10.6% after the FDA extended its review of partner Travere’s Filspari label expansion, resetting the decision deadline to April 13. Travere shares dropped 19%. The FDA classified the latest filing as a “major amendment” but did not request new safety or manufacturing data. The broader biotech sector was little changed.
13 January 2026
···
Travere Therapeutics stock slides as FDA pushes Filspari FSGS decision into April

Travere Therapeutics stock slides as FDA pushes Filspari FSGS decision into April

Travere Therapeutics shares fell 19% Tuesday after the FDA extended its review of Filspari for broader use in kidney disease, pushing the decision deadline to April 13. The stock hit an intraday low of $22.35 before recovering. Travere forecast $127 million in Q4 U.S. net product sales and ended 2025 with $323 million in cash and equivalents. Analyst Joseph Schwartz warned a formal rejection from the FDA remains possible.
13 January 2026
··
Travere Therapeutics TVTX stock slides 5% as FDA decision on Filspari nears

Travere Therapeutics TVTX stock slides 5% as FDA decision on Filspari nears

Travere Therapeutics shares dropped 5.3% to $36.09 Tuesday ahead of the FDA’s Jan. 13 decision on expanding kidney drug Filspari’s label. Options trading surged, with heavy put activity at the $35 strike. Chief Medical Officer Jula Inrig disclosed a planned sale of 15,000 shares to cover taxes. CEO Eric Dube will present at the J.P. Morgan Healthcare Conference on Jan. 12.
6 January 2026
··
Why Travere Therapeutics (TVTX) stock is down today as insider sales hit the tape ahead of a key FDA date

Why Travere Therapeutics (TVTX) stock is down today as insider sales hit the tape ahead of a key FDA date

Travere Therapeutics shares fell 3.8% to $37.39 Tuesday afternoon, outpacing declines in biotech ETFs. SEC filings showed Chief Medical Officer Jula Inrig and Chief Commercial Officer Pieter Heerma sold shares on Dec. 24 under pre-arranged 10b5-1 plans. The moves come weeks before a key FDA decision on Filspari for FSGS, set for Jan. 13, 2026. Trading volume reached about 893,000 shares.
30 December 2025
Travere Therapeutics (TVTX) Stock Watch: Pre‑Market Focus on the Jan. 13 FDA Decision After a 14% Rally

Travere Therapeutics (TVTX) Stock Watch: Pre‑Market Focus on the Jan. 13 FDA Decision After a 14% Rally

Travere Therapeutics shares closed at $40.28 on Dec. 24, up 13.9% after bullish analyst commentary and anticipation of an FDA decision on FILSPARI for FSGS by Jan. 13, 2026. Early pre-market trading Friday showed TVTX around $40.6. The FDA dropped plans for an advisory committee meeting, which some investors see as a positive sign. Trading volume remains light due to the holiday.
26 December 2025
Travere Therapeutics (TVTX) Stock Jumps on Dec. 24, 2025: 52-Week High, FDA Catalyst Ahead, and Analyst Price Targets

Travere Therapeutics (TVTX) Stock Jumps on Dec. 24, 2025: 52-Week High, FDA Catalyst Ahead, and Analyst Price Targets

Travere Therapeutics shares jumped about 15% to over $40 in early trading on Dec. 24, 2025, hitting new highs during a holiday-shortened session. The surge followed investor anticipation of an FDA decision on FILSPARI for FSGS, expected by Jan. 13, 2026. No company news was released that day. The FDA previously waived an advisory committee review for the application.
24 December 2025
·

Stock Market Today

  • FormFactor (FORM) Valuation Questioned After Sharp Share Price Surge
    April 9, 2026, 11:25 PM EDT. FormFactor (FORM) shares soared over 100% year-to-date, driven by optimism in generative AI and high-performance computing demand. The stock closed at $121.07, well above the $84.11 fair value estimate, suggesting the market may have priced in significant future growth. The company's probe cards and early lead in testing next-gen HBM4 chiplets position it to benefit from increasing data center test complexity. However, risks remain, including potential drops in HBM or DRAM demand and tariff impacts that could pressure margins. Analysts caution that current valuations reflect tight margin assumptions and concentrated customer exposure. Investors face the challenge of weighing strong revenue potential against heightened valuation risks amid mixed market sentiment.

Latest article

MARA Holdings Stock Rises Even After Target Cut as Bitcoin Miner Leans Harder Into AI

MARA Holdings Stock Rises Even After Target Cut as Bitcoin Miner Leans Harder Into AI

9 April 2026
MARA Holdings shares rose 1.7% to $9.67 Thursday despite Cantor Fitzgerald cutting its price target to $10. The company recently sold 15,133 bitcoin for $1.1 billion and agreed to repurchase $1 billion in convertible notes at a discount. MARA is expanding into AI and cloud infrastructure, but fourth-quarter revenue fell 6% and it posted a $1.7 billion net loss.
CoreWeave secures fresh $21 billion Meta AI deal as debt push raises stakes

CoreWeave secures fresh $21 billion Meta AI deal as debt push raises stakes

9 April 2026
Meta Platforms signed a new $21 billion deal with CoreWeave for AI cloud computing capacity through 2032, according to a securities filing. CoreWeave shares rose 3.4% in after-hours trading. The agreement adds to a $14.2 billion commitment disclosed last September. CoreWeave also launched $3 billion in convertible notes and upsized a senior-notes deal to $1.75 billion.
Tesla Revives Cheaper EV Push With New Compact SUV as Sales Pressure Builds

Tesla Revives Cheaper EV Push With New Compact SUV as Sales Pressure Builds

9 April 2026
Tesla is developing a lower-cost compact SUV, with initial production planned for Shanghai, Reuters reported Thursday. The company built 408,386 vehicles and delivered 358,023 in the first quarter, leaving its widest gap in at least four years. Reuters said the new SUV likely will not reach production this year. Tesla did not respond to questions about the project.
NIO ES9 Price Starts at 528,000 Yuan as Flagship SUV Bet Faces China EV Slump

NIO ES9 Price Starts at 528,000 Yuan as Flagship SUV Bet Faces China EV Slump

9 April 2026
NIO opened pre-orders for its ES9 flagship SUV Thursday, pricing it at 528,000 yuan with battery or 420,000 yuan under its Battery-as-a-Service plan. March deliveries rose 136% year-on-year, but NIO’s U.S. shares fell 4.9% after the announcement. The ES9 enters a shrinking premium SUV market in China, competing with Li Auto and Aito. CEO William Li warned chip shortages could add up to 10,000 yuan per vehicle.
Plug Power Stock Climbs After 2026 Profit Push, Up to $200M Cost-Cut Plan

Plug Power Stock Climbs After 2026 Profit Push, Up to $200M Cost-Cut Plan

9 April 2026
Plug Power shares rose 2.5% to $2.715 Thursday after the company reaffirmed its target of positive EBITDAS by end-2026 and projected up to $200 million in savings from Project Quantum Leap. The update followed a major electrolyzer project win in Quebec and investor meetings in Toronto and Montreal. Plug reported 2025 revenue of $710 million and a fourth-quarter gross profit of $5.5 million.
Go toTop